Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials
DPP4 inhibitors (DPP4i) are a class of newly developed antidiabetic drugs which preserve incretin hormones and promote postprandial insulin secretion. Although the cardiovascular effect of DPP4 inhibition has been substantially studied, the exact role of DPP4 in cardiovascular disease especially in...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2015/606031 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832552160376651776 |
|---|---|
| author | Jixin Zhong Quan Gong Aditya Goud Srividya Srinivasamaharaj Sanjay Rajagopalan |
| author_facet | Jixin Zhong Quan Gong Aditya Goud Srividya Srinivasamaharaj Sanjay Rajagopalan |
| author_sort | Jixin Zhong |
| collection | DOAJ |
| description | DPP4 inhibitors (DPP4i) are a class of newly developed antidiabetic drugs which preserve incretin hormones and promote postprandial insulin secretion. Although the cardiovascular effect of DPP4 inhibition has been substantially studied, the exact role of DPP4 in cardiovascular disease especially in humans remains elusive. Previous small studies and meta-analyses have suggested a benefit in both surrogate outcomes and cardiovascular events for these agents. However, there was growing evidence in recent years questioning the cardioprotective effect of DPP4i. Further, a signal of heart failure hospitalization in a recent large scale clinical trial SAVOR-TIMI 53 has called into question the safety of these agents and their utility in the treatment of cardiovascular disease. In this review, we will revisit the physiologic function of DPP4 and discuss its role in cardiometabolic disease based on recent experimental and clinical studies. |
| format | Article |
| id | doaj-art-5c085c5e64374cd29796bdc7a1eb2346 |
| institution | Kabale University |
| issn | 2314-6745 2314-6753 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-5c085c5e64374cd29796bdc7a1eb23462025-02-03T05:59:29ZengWileyJournal of Diabetes Research2314-67452314-67532015-01-01201510.1155/2015/606031606031Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical TrialsJixin Zhong0Quan Gong1Aditya Goud2Srividya Srinivasamaharaj3Sanjay Rajagopalan4Department of Immunology, School of Medicine, Yangtze University, Jingzhou, Hubei 434023, ChinaDepartment of Immunology, School of Medicine, Yangtze University, Jingzhou, Hubei 434023, ChinaDivision of Cardiovascular Medicine, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USADivision of Cardiovascular Medicine, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USADivision of Cardiovascular Medicine, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USADPP4 inhibitors (DPP4i) are a class of newly developed antidiabetic drugs which preserve incretin hormones and promote postprandial insulin secretion. Although the cardiovascular effect of DPP4 inhibition has been substantially studied, the exact role of DPP4 in cardiovascular disease especially in humans remains elusive. Previous small studies and meta-analyses have suggested a benefit in both surrogate outcomes and cardiovascular events for these agents. However, there was growing evidence in recent years questioning the cardioprotective effect of DPP4i. Further, a signal of heart failure hospitalization in a recent large scale clinical trial SAVOR-TIMI 53 has called into question the safety of these agents and their utility in the treatment of cardiovascular disease. In this review, we will revisit the physiologic function of DPP4 and discuss its role in cardiometabolic disease based on recent experimental and clinical studies.http://dx.doi.org/10.1155/2015/606031 |
| spellingShingle | Jixin Zhong Quan Gong Aditya Goud Srividya Srinivasamaharaj Sanjay Rajagopalan Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials Journal of Diabetes Research |
| title | Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials |
| title_full | Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials |
| title_fullStr | Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials |
| title_full_unstemmed | Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials |
| title_short | Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials |
| title_sort | recent advances in dipeptidyl peptidase 4 inhibition therapy lessons from the bench and clinical trials |
| url | http://dx.doi.org/10.1155/2015/606031 |
| work_keys_str_mv | AT jixinzhong recentadvancesindipeptidylpeptidase4inhibitiontherapylessonsfromthebenchandclinicaltrials AT quangong recentadvancesindipeptidylpeptidase4inhibitiontherapylessonsfromthebenchandclinicaltrials AT adityagoud recentadvancesindipeptidylpeptidase4inhibitiontherapylessonsfromthebenchandclinicaltrials AT srividyasrinivasamaharaj recentadvancesindipeptidylpeptidase4inhibitiontherapylessonsfromthebenchandclinicaltrials AT sanjayrajagopalan recentadvancesindipeptidylpeptidase4inhibitiontherapylessonsfromthebenchandclinicaltrials |